Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06709820 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4060874 in Healthy Participants
A Phase 1 study of Healthy Participants, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 2
- Study locations
NCT06709820: Active Phase 1 study of Healthy Participants, sponsored by Eli Lilly and Company.
NCT06709820 is a Phase 1 study of Healthy Participants that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 132 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (103% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06709820, a Phase 1 study of Healthy Participants, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 18 study visits.
Primary Outcome
Number of participants with one or more TEAEs and SAEs.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY4060874
Study Locations (2)
Texas
- Fortrea, Inc. - Dallas
Other
- Lilly Centre for Clinical Pharmacology - Singapore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2024-12-02 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What the registry record for NCT06709820 still lists
NCT06709820 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (103% higher).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06709820 reports a single indexed study location in Texas, Other.
Frequently Asked Questions
What is clinical trial NCT06709820 about?
NCT06709820 is a clinical study titled "A Study of LY4060874 in Healthy Participants". The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 18 study visits.
What is the current status of trial NCT06709820?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2024-12-02. Estimated completion is 2026-03.
What conditions does trial NCT06709820 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT06709820?
The interventions under investigation include: Placebo (DRUG), LY4060874 (DRUG).
Who is sponsoring clinical trial NCT06709820?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06709820 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06709820's enrollment target sits among peer trials
132 11th of 119 higher than 108 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI